|
|
Gilead Sciences Inc (NASDAQ: GILD) |
|
Price: $146.3000
$-0.11 
-0.075%
|
| Day's High:
| $146.35000610351562
| Week Perf:
| 0.45 %
|
| Day's Low: |
$ 142.94 |
30 Day Perf: |
5.74 % |
| Volume (M): |
4,264,938 |
52 Wk High: |
$ 157.29 |
| Volume (M$): |
$ 0 |
52 Wk Avg: |
$131.76 |
| Open: |
$144.00 |
52 Wk Low: |
$108.46 |
|
|
| Market Capitalization (Millions $) |
181,851 |
| Shares
Outstanding (Millions) |
1,243 |
| Employees |
17,000 |
| Revenues (TTM) (Millions $) |
30,457 |
| Net Income (TTM) (Millions $) |
-3,240 |
| Cash Flow (TTM) (Millions $) |
2,485 |
| Capital Exp. (TTM) (Millions $) |
609 |
Business Description
Company Profile: Gilead Sciences, Inc.
Overview:
Gilead Sciences, Inc. is a leading biopharmaceutical company dedicated to discovering, developing, and commercializing innovative therapeutics to improve the health and quality of life for patients with life-threatening diseases around the globe. Based in Foster City, California, the company has established itself as a pioneer in the field of antiviral and anti-infective therapies, with a strong focus on areas including HIV, hepatitis, and infectious diseases.
Key Products:
Gilead has an extensive portfolio of marketed products, many of which have become standard therapies in their respective categories. They include:
- Viread (tenofovir disoproxil fumarate): Used in combination with other antiretroviral agents for the treatment of HIV infection, both in the United States and internationally.
- Emtriva (emtricitabine): Another key antiretroviral medication approved for use in the treatment of HIV infection in adults; a fixed-dose combination with Viread is currently under development.
- AmBisome (liposomal amphotericin B): Indicated for the treatment of serious fungal infections and marketed in over 45 countries globally. Gilead collaborates with Fujisawa Healthcare, Inc. for its promotion in the U.S.
- Hepsera (adefovir dipivoxil): Prescribed for chronic hepatitis B treatment, marketed in both the U.S. and certain international markets, including Europe.
- Tamiflu (oseltamivir phosphate): An antiviral medication used for the prevention and treatment of influenza, marketed worldwide in collaboration with Roche.
- Vistide (cidofovir): Indicated for the treatment of cytomegalovirus (CMV) retinitis in AIDS patients, marketed in the U.S. and through a partnership with Pfizer in various countries.
Commercial Operations:
Gilead operates robust U.S. and international sales teams, with marketing affiliates strategically positioned across Europe, Asia, and Australia. The company utilizes a comprehensive sales strategy involving direct engagement with healthcare providers, hospitals, and clinics to ensure broad access to its products.
Collaborative Relationships:
Gilead is committed to collaboration with various partners in the pharmaceutical industry to enhance its research and development capabilities. Key collaborations include:
- Archemix Corporation: Partnership involving a license for SELEX technology to discover aptamers.
- Chiron Corporation: Licensing agreement for small molecule therapeutics aimed at hepatitis C.
- GlaxoSmithKline: Exclusive rights granted for Hepseras commercialization in Asia and Latin America.
Recent Developments:
As of 2023, Gilead continues to expand its portfolio with ongoing research and development endeavors. The company has invested in next-generation antiviral therapies, including long-acting formulations for HIV, as well as treatments for emerging infectious diseases. Its commitment to innovation is evident in the continuous expansion and improvement of its product pipeline.
Conclusion:
Gilead Sciences, Inc. remains a key player in the biopharmaceutical landscape, with a focus on advancing healthcare solutions for patients with critical health needs. Through strategic collaborations and a commitment to research, Gilead aims to sustain its leadership in antiviral therapies and address unmet medical needs in infectious diseases.
Company Address: 333 Lakeside Drive Foster City 94404 CA
Company Phone Number: 574-3000 Stock Exchange / Ticker: NASDAQ GILD
|
|
|
Customers Net Income grew by |
GILD's Customers Net Profit Margin grew to |
63.2 % |
3.19 %
|
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Business Update
Published Fri, Nov 7 2025 3:06 PM UTC
Gilead s ASCENT-07 Study Update: A Mixed Bag Amidst Competitive Pressure in the Pharmaceutical Sector Foster City, California - Gilead Sciences, Inc. (Nasdaq: GILD) has recently provided an update regarding its Phase 3 ASCENT-07 study, which aimed to evaluate the efficacy of Trodelvy (sacituzumab govitecan-hziy) as a first-line treatment in patients with HR+/HER2-negative me...
|
| Business Update
Published Thu, Oct 23 2025 3:41 PM UTC
Gilead Sciences, Inc. (Nasdaq: GILD) is positioning itself at the forefront of liver disease research with its upcoming presentation at The Liver Meeting 2025, an event organized by the American Association for the Study of Liver Diseases (AASLD) scheduled for November 7-11 in Washington, D.C. The company plans to unveil notable findings from over 35 accepted abstracts, focu...
|
| Business Update
Published Mon, Oct 20 2025 8:05 AM UTC
In a pivotal leap for antiviral research and development, Gilead Sciences, Inc. (Nasdaq: GILD) is set to showcase groundbreaking findings at IDWeek 2025, scheduled from October 19-22 in Atlanta, GA. With a comprehensive agenda featuring 34 presentations on the latest advances in HIV, viral hepatitis, respiratory viruses, and other viruses of pandemic potential, Gilead reinfo...
|
| Business Update
Published Mon, Oct 13 2025 7:50 PM UTC
In the rapidly evolving landscape of oncology, Gilead Sciences, Inc. and its subsidiary Kite are steadfastly positioning themselves as leaders in cancer care innovation. The recent European Society for Medical Oncology (ESMO) 2025 Congress showcased groundbreaking developments, particularly in the treatment of advanced triple-negative breast cancer (TNBC) through the Phase ...
|
| Business Update
Published Wed, Sep 3 2025 4:14 PM UTC
In an era where health and innovation intertwine, Gilead Sciences (Nasdaq: GILD) demonstrates a decisive commitment to enhancing its manufacturing capabilities while simultaneously addressing pressing global health challenges. The company recently celebrated a groundbreaking ceremony for its new Pharmaceutical Development and Manufacturing (PDM) Technical Development Center ...
|
Fundamental Analysis
| Per Share |
Current |
| Earnings (TTM) |
-2.67 $ |
| Revenues (TTM) |
24.5 $
|
| Cash Flow (TTM) |
2 $ |
| Cash |
-
|
| Book Value |
9.52 $
|
| Dividend (TTM) |
3.22 $ |
| Efficiency
|
Current |
| Revenue per Employee
(TTM) |
1,791,588 |
| Net
Income per Employee (TTM) |
-190,588 |
| Receivable Turnover Ratio (TTM) |
6.15 |
| Inventory Turnover Ratio (TTM) |
3.35 |
| Asset Turnover Ratio (TTM) |
0.54 |
|
|
| Per Share |
|
| Earnings (TTM) |
-2.67 $
|
| Revenues (TTM) |
24.5 $ |
| Cash Flow (TTM) |
2 $ |
| Cash |
-
|
| Book Value |
9.52 $ |
| Dividend (TTM) |
3.22 $ |
|
|
| |
| U S |
|
 70.78 % |
of total Revenue |
| Europe |
|
16.44 % |
of total Revenue |
| Rest of World |
|
12.77 % |
of total Revenue |
| Total product sales |
|
99.8 % |
of total Revenue |
| Total product sales U S |
|
70.78 % |
of total Revenue |
| Total product sales Europe |
|
16.34 % |
of total Revenue |
| Total product sales Rest of World |
|
12.69 % |
of total Revenue |
| Total HIV |
|
72.27 % |
of total Revenue |
| Total HIV U S |
|
57.53 % |
of total Revenue |
| Total HIV Europe |
|
8.72 % |
of total Revenue |
| Total HIV Rest of World |
|
6.02 % |
of total Revenue |
| Biktarvy |
|
48.29 % |
of total Revenue |
| Biktarvy U S |
|
36.97 % |
of total Revenue |
| Biktarvy Europe |
|
6.28 % |
of total Revenue |
| Biktarvy Rest of World |
|
5.06 % |
of total Revenue |
| Descovy |
|
11.59 % |
of total Revenue |
| Descovy U S |
|
10.93 % |
of total Revenue |
| Descovy Europe |
|
0.33 % |
of total Revenue |
| Descovy Rest of World |
|
0.33 % |
of total Revenue |
| Genvoya |
|
3.79 % |
of total Revenue |
| Genvoya U S |
|
3.09 % |
of total Revenue |
| Genvoya Europe |
|
0.47 % |
of total Revenue |
| Genvoya Rest of World |
|
0.23 % |
of total Revenue |
| Odefsey |
|
3.18 % |
of total Revenue |
| Odefsey U S |
|
2.2 % |
of total Revenue |
| Odefsey Europe |
|
0.85 % |
of total Revenue |
| Odefsey Rest of World |
|
0.13 % |
of total Revenue |
| Symtuza - Revenue share |
|
1.98 % |
of total Revenue |
| Symtuza - Revenue share U S |
|
1.54 % |
of total Revenue |
| Symtuza - Revenue share Europe |
|
0.4 % |
of total Revenue |
| Symtuza - Revenue share Rest of World |
|
0.04 % |
of total Revenue |
| Yeztugo |
|
2.39 % |
of total Revenue |
| Yeztugo U S |
|
2.27 % |
of total Revenue |
| Yeztugo Rest of World |
|
0.1 % |
of total Revenue |
| Other HIV |
|
1.05 % |
of total Revenue |
| Other HIV U S |
|
0.52 % |
of total Revenue |
| Other HIV Europe |
|
0.39 % |
of total Revenue |
| Other HIV Rest of World |
|
0.13 % |
of total Revenue |
| Total Oncology |
|
11.64 % |
of total Revenue |
| Total Oncology U S |
|
5.79 % |
of total Revenue |
| Total Oncology Europe |
|
3.99 % |
of total Revenue |
| Total Oncology Rest of World |
|
1.85 % |
of total Revenue |
| Total Cell Therapy |
|
5.85 % |
of total Revenue |
| Total Cell Therapy U S |
|
2.16 % |
of total Revenue |
| Total Cell Therapy Europe |
|
2.63 % |
of total Revenue |
| Total Cell Therapy Rest of World |
|
1.06 % |
of total Revenue |
| Tecartus |
|
1.08 % |
of total Revenue |
| Tecartus U S |
|
0.43 % |
of total Revenue |
| Tecartus Europe |
|
0.53 % |
of total Revenue |
| Tecartus Rest of World |
|
0.11 % |
of total Revenue |
| Yescarta |
|
4.77 % |
of total Revenue |
| Yescarta U S |
|
1.72 % |
of total Revenue |
| Yescarta Europe |
|
2.1 % |
of total Revenue |
| Yescarta Rest of World |
|
0.96 % |
of total Revenue |
| Trodelvy |
|
5.78 % |
of total Revenue |
| Trodelvy U S |
|
3.64 % |
of total Revenue |
| Trodelvy Europe |
|
1.36 % |
of total Revenue |
| Trodelvy Rest of World |
|
0.78 % |
of total Revenue |
| Total Liver Disease |
|
11.02 % |
of total Revenue |
| Total Liver Disease U S |
|
5.2 % |
of total Revenue |
| Total Liver Disease Europe |
|
2.44 % |
of total Revenue |
| Total Liver Disease Rest of World |
|
3.38 % |
of total Revenue |
| Livdelzi |
|
1.91 % |
of total Revenue |
| Livdelzi U S |
|
1.65 % |
of total Revenue |
| Livdelzi Europe |
|
0.26 % |
of total Revenue |
| Sofosbuvir Velpatasvir |
|
4.07 % |
of total Revenue |
| Sofosbuvir Velpatasvir U S |
|
2.03 % |
of total Revenue |
| Sofosbuvir Velpatasvir Europe |
|
0.86 % |
of total Revenue |
| Sofosbuvir Velpatasvir Rest of World |
|
1.18 % |
of total Revenue |
| Vemlidy |
|
3.41 % |
of total Revenue |
| Vemlidy U S |
|
1.31 % |
of total Revenue |
| Vemlidy Europe |
|
0.19 % |
of total Revenue |
| Vemlidy Rest of World |
|
1.9 % |
of total Revenue |
| Other Liver Disease |
|
1.64 % |
of total Revenue |
| Other Liver Disease U S |
|
0.22 % |
of total Revenue |
| Other Liver Disease Europe |
|
1.12 % |
of total Revenue |
| Other Liver Disease Rest of World |
|
0.3 % |
of total Revenue |
| Veklury |
|
2.07 % |
of total Revenue |
| Veklury U S |
|
1.61 % |
of total Revenue |
| Veklury Europe |
|
0.2 % |
of total Revenue |
| Veklury Rest of World |
|
0.26 % |
of total Revenue |
| Total Other |
|
2.82 % |
of total Revenue |
| Total Other U S |
|
0.66 % |
of total Revenue |
| Total Other Europe |
|
0.96 % |
of total Revenue |
| Total Other Rest of World |
|
1.19 % |
of total Revenue |
| AmBisome |
|
1.98 % |
of total Revenue |
| AmBisome U S |
|
0.1 % |
of total Revenue |
| AmBisome Europe |
|
0.85 % |
of total Revenue |
| AmBisome Rest of World |
|
1.03 % |
of total Revenue |
| Other |
|
0.83 % |
of total Revenue |
| Other U S |
|
0.56 % |
of total Revenue |
| Other Europe |
|
0.11 % |
of total Revenue |
| Other Rest of World |
|
0.16 % |
of total Revenue |
| Royalty contract and other revenues |
|
0.2 % |
of total Revenue |
| Royalty contract and other revenues Europe |
|
0.11 % |
of total Revenue |
| Royalty contract and other revenues Rest of World |
|
0.09 % |
of total Revenue |
|
|
7.59%